
Chris Arendt, CSO of Takeda, likens the AI overhaul at the pharma to gutting and rebuilding an old house, from the plumbing and electrical up, while you’re still living there. In a Fireside Chat at Grand Rounds U.S. in Seattle, Arendt sat down with Editor in Chief Simone Fishburn to discuss how Takeda is integrating AI across R&D, in and beyond the science, while still executing on the active programs in drug development. View full story: https://www.biocentury.com/article/659807 #Artif...
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

Ep. 115 - Initiate's Owens on what it takes to be AI-native

Ep. 114 - Roivant’s Matt Gline on commercial launches and the future of the vant model

Ep. 113 - Frank Jiang on Hengrui’s rise and China’s new era of biopharma dealmaking

Ep. 111 - McGill's Angela Genge on why ALS drug development is turning a corner
Free AI-powered recaps of The BioCentury Show and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.